SG10201609580YA - Treating dyspnea associated with acute heart failure with relaxin - Google Patents

Treating dyspnea associated with acute heart failure with relaxin

Info

Publication number
SG10201609580YA
SG10201609580YA SG10201609580YA SG10201609580YA SG10201609580YA SG 10201609580Y A SG10201609580Y A SG 10201609580YA SG 10201609580Y A SG10201609580Y A SG 10201609580YA SG 10201609580Y A SG10201609580Y A SG 10201609580YA SG 10201609580Y A SG10201609580Y A SG 10201609580YA
Authority
SG
Singapore
Prior art keywords
relaxin
heart failure
acute heart
dyspnea associated
treating dyspnea
Prior art date
Application number
SG10201609580YA
Other languages
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of SG10201609580YA publication Critical patent/SG10201609580YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201609580YA 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin SG10201609580YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
SG10201609580YA true SG10201609580YA (en) 2016-12-29

Family

ID=40834101

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201609580YA SG10201609580YA (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin
SG2013038260A SG191587A1 (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013038260A SG191587A1 (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin

Country Status (30)

Country Link
US (7) US8053411B2 (https=)
EP (2) EP2288373B1 (https=)
JP (4) JP5651586B2 (https=)
CN (3) CN102036679A (https=)
AR (1) AR071810A1 (https=)
AU (1) AU2009246114B2 (https=)
BR (1) BRPI0913011A2 (https=)
CA (1) CA2724540C (https=)
CR (1) CR11749A (https=)
CY (1) CY1116925T1 (https=)
DK (1) DK2288373T3 (https=)
EA (2) EA201500552A1 (https=)
ES (1) ES2546287T3 (https=)
GB (2) GB2459983B (https=)
HK (1) HK1202054A1 (https=)
HR (1) HRP20150845T1 (https=)
HU (1) HUE025483T2 (https=)
IL (3) IL208992A (https=)
MA (1) MA32389B1 (https=)
MX (1) MX2010012450A (https=)
MY (2) MY159803A (https=)
NZ (3) NZ589009A (https=)
PL (1) PL2288373T3 (https=)
PT (1) PT2288373E (https=)
SG (2) SG10201609580YA (https=)
SI (1) SI2288373T1 (https=)
TW (1) TWI386202B (https=)
UA (1) UA99953C2 (https=)
WO (1) WO2009140659A2 (https=)
ZA (1) ZA201007449B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912559A2 (pt) * 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2544706B1 (en) 2010-03-10 2015-06-17 The University Of Melbourne Modulating aquaporins with relaxin
US9465039B2 (en) 2010-08-06 2016-10-11 Mycartis Nv Perlecan as a biomarker for renal dysfunction
EA030886B1 (ru) * 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2864100A1 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) * 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016010087A (es) * 2014-02-03 2016-10-07 Novartis Ag Filtros para equipos de infusion.
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
US20170100460A1 (en) * 2014-06-13 2017-04-13 Novartis Ag Use of serelaxin to reduce gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー 免疫抑制薬及び処置方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
TW200800206A (en) 2005-07-11 2008-01-01 Abbott Lab Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
BRPI0912559A2 (pt) 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica

Also Published As

Publication number Publication date
PL2288373T3 (pl) 2015-11-30
WO2009140659A2 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
BRPI0913011A2 (pt) 2019-09-03
US20120040903A1 (en) 2012-02-16
US20150320834A1 (en) 2015-11-12
HK1187550A1 (zh) 2014-04-11
MX2010012450A (es) 2011-03-21
CN106177914A (zh) 2016-12-07
CN103212063A (zh) 2013-07-24
JP5875646B2 (ja) 2016-03-02
EP2288373B1 (en) 2015-06-24
JP2015013870A (ja) 2015-01-22
JP2016053040A (ja) 2016-04-14
IL208992A0 (en) 2011-01-31
JP2011520918A (ja) 2011-07-21
US20130116181A1 (en) 2013-05-09
HK1139051A1 (en) 2010-09-10
EP2288373A2 (en) 2011-03-02
EA201500552A1 (ru) 2016-07-29
EA201001771A1 (ru) 2011-06-30
GB0908432D0 (en) 2009-06-24
CA2724540A1 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
MY158327A (en) 2016-09-30
US9579363B2 (en) 2017-02-28
AR071810A1 (es) 2010-07-14
SG191587A1 (en) 2013-07-31
HK1202054A1 (en) 2015-09-18
HK1140693A1 (en) 2010-10-22
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US9066916B2 (en) 2015-06-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
HK1151229A1 (en) 2012-01-27
AU2009246114A1 (en) 2009-11-19
DK2288373T3 (en) 2015-09-28
SI2288373T1 (sl) 2015-12-31
GB2459983B (en) 2010-04-28
JP5638044B2 (ja) 2014-12-10
UA99953C2 (uk) 2012-10-25
MY159803A (en) 2017-02-15
NZ598709A (en) 2013-09-27
EP2829280A1 (en) 2015-01-28
NZ701038A (en) 2016-01-29
US8053411B2 (en) 2011-11-08
EA022948B1 (ru) 2016-03-31
GB0918132D0 (en) 2009-12-02
GB2462221B (en) 2010-09-01
TW200948353A (en) 2009-12-01
US20170151311A1 (en) 2017-06-01
CY1116925T1 (el) 2017-04-05
US20100048475A1 (en) 2010-02-25
US8415301B2 (en) 2013-04-09
JP5651586B2 (ja) 2015-01-14
IL228244A (en) 2016-10-31
HUE025483T2 (en) 2016-02-29
AU2009246114B2 (en) 2013-01-31
ES2546287T3 (es) 2015-09-22
CR11749A (es) 2011-02-11
IL208992A (en) 2013-09-30
GB2459983A (en) 2009-11-18
PT2288373E (pt) 2015-10-19
CA2724540C (en) 2014-07-08
GB2462221A (en) 2010-02-03
TWI386202B (zh) 2013-02-21
HRP20150845T1 (hr) 2015-11-06
US20120040902A1 (en) 2012-02-16
JP2013040174A (ja) 2013-02-28
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
ZA201007449B (en) 2011-06-29
IL247351A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MY158327A (en) Treating dyspnea associated with acute heart failure with relaxin
PL2128324T3 (pl) Traktowanie tekstyliów
IL215975A (en) Heart failure device
EP2322076A4 (en) ENDOSCOPE OF TREATMENT
GB0823213D0 (en) Treatment
GB0802116D0 (en) Treatment
EP2288366A4 (en) METHOD FOR TREATING CHRONIC HEART FAILURE
GB0822011D0 (en) Treatment
IL207583A0 (en) Treating hyperglycemia with 25-hydroxyvitamin d3
IL219565A0 (en) Method for treating heart failure with stresscopin-like peptides
ZA200905792B (en) Banana treatments
IL207584A0 (en) Treating hypertension with 25-hydroxyvitamin d3
GB0811992D0 (en) Treatment
GB0906436D0 (en) Circulation Stimulator
GB0806047D0 (en) Treatment of heart failure
GB0822077D0 (en) Novel treatments
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB0814722D0 (en) Treatment monitoring
HK1139051B (en) Methods of treating dyspnea associated with acute heart failure
GB0813824D0 (en) Textile treatment
PL386080A1 (pl) Zbiornik, zwłaszcza sanitarno-higieniczny do mycia i kąpieli
GB2465211B (en) Treatment Solution
GB0800773D0 (en) Water treatment
GB0914371D0 (en) Treating wood